Handelsavisen
prelaunch
Companies Healthcare 600774.SS
60
600774.SS Shanghai Stock Exchange Pharmaceuticals

600774.Ss

¥8,27
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,4B CNY
P/E
EV / Rev
Div yield
0,00 %
Op margin
-0,8 %
ROE
-0,9 %
Net margin
-1,2 %
Debt / equity
0,65
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-0,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 600774.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 600774.SS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.65, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.44, suggesting potential challenges in meeting short-term obligations. The price-to-book ratio of 1.38 implies that the market values the company at a premium to its book value, while the negative return on equity of -0.88% and return on assets of -0.41% highlight underperformance in generating returns for shareholders and asset utilization.

    Profitability metrics show a significant decline, with a net loss of 14,587,170 CNY and an operating loss of 9,727,810 CNY. Gross profit of 641,291,650 CNY is a positive indicator, but it is insufficient to offset the operating and net losses. The company's return on equity and return on assets are below the industry median, indicating that it is not generating returns at a level typical for its sector.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with market-specific downturns or regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets or product lines.

    The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year. The operating cash flow of 192,778,250 CNY provides some liquidity, but the negative free cash flow of -1,941,850 CNY and capital expenditure of -60,497,590 CNY suggest that the company is investing in its operations while facing cash flow constraints. The outlook for the next fiscal year is not provided, but the current financial performance raises concerns about future growth.

    The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The company's debt load, with long-term debt of 1,074,711,820 CNY, is a significant portion of its total liabilities, which could impact its financial flexibility. The low dilution risk is supported by the absence of dilutive securities and the alignment of basic and diluted shares outstanding.

    Recent events, as reflected in the financial data, include a net loss and a decline in profitability. The company's last actual EPS was 0.02 CNY, and its last actual revenue was 551,395,000 CNY, both of which are below the revenue of 1,175,401,780 CNY reported in the most recent financial snapshot. These figures suggest a decline in performance, which may be attributed to market conditions, operational inefficiencies, or other factors not disclosed in the available data.

    Key takeaways
    • The company is experiencing a net loss and operating loss, indicating poor profitability.
    • The company's liquidity position is medium, with a current ratio of 0.44, suggesting potential challenges in meeting short-term obligations.
    • The company's debt-to-equity ratio of 0.65 indicates a moderate reliance on debt financing.
    • The company's return on equity and return on assets are below the industry median, indicating underperformance in generating returns for shareholders and asset utilization.
    • The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year and a lack of disclosed geographic or segment diversification.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥8,27
    Market cap
    ¥2.29B
    Enterprise value
    ¥3.36B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    17.4x
    P / B
    1.4x
    P / Tangible book
    1.4x
    Tangible book
    ¥1.66B
    Net cash
    -¥1.07B
    Current ratio
    0.4
    Debt / equity
    0.7
    ROA
    -0.4%
    ROE
    -0.9%
    Cash conversion
    -1322.0%
    CapEx / revenue
    -5.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-0,8 %Below median
    Net Margin-1,2 %Below median
    ROE-0,9 %Below median
    Capex / Rev-5,1 %Above median
    D/E0,65Bottom quartile
    Cash Conv-13,22Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 600774.SS Market data — financials · 2026-05-27
    • Hanshang Group Co Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Leadership

    • Fang YangPresident, Director
    • Zeqing WeiExecutive Vice President

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    600774.SSCanonical
    Shanghai Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage